The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1692
December 25, 2023
View Complete Issue         Table of Contents 2019 
Tirzepatide (Zepbound) for Chronic Weight Management
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Tirzepatide (Zepbound) for Chronic Weight Management
December 25, 2023 (Issue: 1692)
The injectable glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide, which was approved by the FDA as Mounjaro for treatment of type 2 diabetes in 2022, has now been approved as Zepbound...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Tirzepatide (Zepbound) for Chronic Weight Management
Article code: 1692c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.